Stem Cell Related Patent Number US6486381

Genetically engineered mice containing alterations in the genes encoding retinoic acid receptor proteins

Chambon, Pierre; Blaesheim, France

This invention describes a novel transgenic mouse which is deficient in the normal expression of one or more members of the RAR or RXR class of receptors. Further disclosed are cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such a deficiency. The authors describe ways in which such a transgenic mouse is useful in the identification of isoforms of retinoic acid or the retinoid X receptor-?a (RXR?a), bound by an agent. Also disclosed are properties in which the transgenic mouse contains heterozygous disruption in exon 4 of the gene encoding retinoid X receptor-?a (RXR?a), while exhibiting postnatal growth deficiency. Also provided are uses of such mammalian cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.

Application Number: US1999000426894

Date Filed: 10/26/99

Dated Published: 11/26/00

Assignee: Institut National de la Sante et de la Recherche Medicale, Paris, France
Centre National de la Recherche Scientifique, Paris, France
Universite Louis Pasteur, Strasbourg, France
Bristol Myers Squibb Company, Princeton, NJ, USA